Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
about
Repeat IGRA testing in Canadian health workers: conversions or unexplained variability?Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor TherapyInterferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?Discordance of tuberculin skin test and interferon gamma release assay in recently exposed household contacts of pulmonary TB cases in Brazil.Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review.In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection.Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.Comparison of interferon-γ release assay to two cut-off points of tuberculin skin test to detect latent Mycobacterium tuberculosis infection in primary health care workersYear in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imagingImpact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB gold in-tube assay.HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study.The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.Diagnosis and treatment of latent tuberculosis infection.Comparison of the Prevalence of Latent Tuberculosis Infection among Non-Dialysis Patients with Severe Chronic Kidney Disease, Patients Receiving Dialysis, and the Dialysis-Unit Staff: A Cross-Sectional Study.Cough Aerosol Cultures of Mycobacterium tuberculosis: Insights on TST / IGRA Discordance and Transmission DynamicsCombinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk StratificationCytokine Patterns in Tuberculosis Infection; IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from Uninfected Controls.Effects of acute critical illnesses on the performance of interferon-gamma release assayChallenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers.Inflammatory markers and clinical characteristics for predicting persistent positivity of interferon gamma release assay in dialysis populationAntigen-Specific IFN-γ Responses Correlate with the Activity of M. tuberculosis Infection but Are Not Associated with the Severity of Tuberculosis Disease.Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.Preventing the Transmission of Tuberculosis in Health Care Settings: Administrative Control.Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence.Tuberculosis in healthcare workers - a narrative review from a German perspectiveIFN-γ release assay conversions and reversions. Challenges with serial testing in U.S. health care workers.Update in tuberculosis and nontuberculous mycobacterial infections 2013.Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting.Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of Mycobacterium tuberculosis Infection.Managing tuberculosis infection in children in the USA: an update.Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT.(®)TB and QFT-GIT).Latent Tuberculosis Infection Test Agreement in the National Health and Nutrition Examination Survey.Negative Tuberculin Skin Test and Prediction of Reversion of QuantiFERON Interferon Gamma Release Assay in US Healthcare Workers.Detecting New Mycobacterium tuberculosis Infection. Time for a More Nuanced Interpretation of QuantiFERON Conversions.Poor agreement between diagnostic tests for latent tuberculosis infection among HIV-infected persons in Hong Kong.Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-γ-releasing assay: an exploratory randomized controlled trial.It is high time to reevaluate QuantiFERON-TB gold for clinical practice.Repeatability of QuantiFERON-TB gold in-tube assay results near cut-off points.Discordance of two interferon-γ release assays and tuberculin skin test in patients with uveitis.The elusive "gold" standard for detecting Mycobacterium tuberculosis infection.
P2860
Q21133739-9D049098-15C4-4D04-BBC6-33A015AA479FQ27005716-231C44DD-F3EA-4E27-9121-B497E0BAC200Q28077178-BBF50A12-751F-4A16-B938-2BA04AC00E44Q33599396-B4A7CB4B-FBAE-4C37-A32C-C900492E2304Q33792760-938957AE-C7AC-48FF-9BF3-23CD6AE0A5E3Q33824247-1F1803E2-4A25-4728-93EB-24F97BF9F644Q33882852-88239FFA-8C8F-495D-9BCA-781EFC6C8E9AQ34066281-AAB3A615-7D33-4000-BE1A-A9D9D37CBA27Q34117376-4CFB131E-1991-4462-8507-1B1F64461014Q34365728-E4766013-A44B-4336-9665-DA77EB949322Q34753407-E84C5A87-A285-4314-8791-0CAE7360ED76Q35261953-FB996CD1-A310-4AE9-890A-8AC41C3D0779Q35307280-5B6A10DF-DBE4-4B6B-97AF-69303D2FEF13Q35547610-2FD0F136-8AD1-41CD-B350-4AD2DF07A559Q35783572-BCD6ADB6-B124-4228-9575-9F2B92E50045Q36128602-1E174674-CCE2-4F68-B4A7-382C14D94E88Q36148431-89B3F2CB-BB27-4781-BE47-6C66FDD1E604Q36501008-691B405A-0170-4C77-B148-4655F4939547Q37304401-BFCC2927-C0BA-4275-96F7-9EE0AC4B7059Q37310597-BA205B3A-770C-4BDA-AA75-53C41A89F52BQ37500859-3A341F3B-8126-4E16-8535-A869BA8DC433Q37544916-44CDD2C5-F4C3-49D8-A77D-34FE379B22BEQ37599991-08238AFE-3E46-4BC5-804A-35ACD70A4618Q37649784-EB4FAA6D-64CB-4CAB-83D9-3A8CFAA03AF4Q37699705-10ABB8BD-6054-4689-8D8C-D441C2139EADQ38180469-49B9C41A-7FB3-4C39-9210-6A64F4CA7C78Q38204777-61A33409-71CA-48B2-9C16-665964C6D177Q38404818-22B7FF04-DAFC-4ACD-A9DB-544CD35C8503Q38664922-2B474E44-1770-4918-80D5-F277ACE85349Q38831038-A6F8D1E1-6D07-4405-B8AE-904F0A18C98DQ39433439-CA04E433-2283-4E94-A4B4-D1A875F334A8Q39987562-9B583933-B265-41A6-A934-AABDE09CB782Q40052102-C42B0947-BC95-4410-AADA-7B41DFEEAD8CQ40099727-BC48EEA7-A8B4-4D33-B88B-9A9303693D0FQ40696371-F9DFA0EB-938C-4254-8D12-75C50B5BD722Q41530000-EF00CA27-047D-41FA-BCB6-752D32DB79CCQ42872257-384BC0DA-497D-4423-B876-3E1AADAEE2B4Q43109576-28D7451B-B122-45B9-96B1-DBD102DFE9C1Q45118065-E5DAC166-7873-46BE-AF4B-F8D4D04BDA23Q46162480-AC6FBAF0-821F-4D0B-870F-E417BFD327DF
P2860
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
@ast
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
@en
type
label
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
@ast
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
@en
prefLabel
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
@ast
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
@en
P2093
P2860
P1476
Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice
@en
P2093
Adithya Cattamanchi
Charles E McCulloch
Edward A Graviss
John Z Metcalfe
Justin D Lew
P2860
P304
P356
10.1164/RCCM.201203-0430OC
P407
P577
2012-10-26T00:00:00Z